Table 1. Virological and immunological monitoring of the four groups of solid-organ transplant recipients with or without HCMV infection reactivation.

Follow-up(days)	T-cell count/µl blood median (range)								HCMV infection
	Absolute				Specific				Onset	Duration	DNA peak
	CD4+		CD8+		CD4+		CD8+		Median daysPosttx (range)	Median days (range)	Mediancopies/mlblood (range)	Median days post tx (range)
	Onset1	End1	Onset	End	Onset	End	Onset	End
Group 1 (no HCMV reactivation, n = 7, 6 KTR and 1 HTR)
1–365	604	542	548	703	4.8	2.9	2.2	40.0	NA	NA	NA	NA
	(257–1,515)	(191–1,458)	(239–879)	(267–1,414)	(0.5–10.5)	(0.7–63.8)	(0.5–94.8)	(3.2–87.3)
Group 2 (HCMV reactivation controlled by specific CD4+ and CD8+ T-cells, n = 14, 12 KTR and 2 HTR)
1–365	488	677	300	573	3.6	5.9	8.7	67.7	34	120	1,300	58
	(832,159)	(228–911)	(58–1154)	(253–1,862)	(0.1–16.4)	(0.4–23.8)	(0.1–87.1)	(18.3–220.8)	(12–113)	(6–363)	(200–35,000)	(14–226)
Group 3 (HCMV reactivation temporarily controlled by specific CD8+ T-cells, n = 9, 4 KTR and 5 HTR)
1–902	506	535	218	452	0.1	0.6	0.4	22.3	30	116	10,200	44
	(107–1,003)	(167–1,652)	(92–372)	(133–1,363)	(0.1–0.3)	(0.1–6.8)	(0.1–11.4)	(0.5–90.5)	(6–44)	(30–399)	(1,950–259,000)	(18–52)
91–3652	444	394	554	597	0.8	0.7	27	55.9			350	110
	(232–1,685)	(189–1,446)	(329–1,136)	(159–870)	(0.4–1.3)	(0.3–2.9)	(8.4–66.3)	(21–212.6)			(<25–287,200)	(91–346)
Group 4 (uncontrolled HCMV reactivation and need for antiviral treatment, n = 9, 3 KTR and 6 HTR)
1–365	198	401	195	1021	0.1	0.7	0.8	29.5	25	182	308,0003	48
	(22–975)	(250–1,118)	(60–815)	(727–2,391)	(0.1–0.9)	(0.1–6.7)	(0.1–8.7)	(5.3–323.5)	(14–37)	(50–347)	(119,900–858,000)	(41–136)

NA, not applicable.

¹Follow-up.

²Patients of this group showed HCMV specific CD8⁺ only, until about 3 months after transplantation, then developed HCMV-specific CD4⁺ T-cells.

³In some cases, clinicians preferred initiating antiviral therapy after reaching 100,000 (instead of 300,000) DNA copies/ml blood due to presence of end-organ disease.